Ropes & Gray Advised Tanabe Pharma Corporation in the $2.5 Billion Sale of Global Rights to its RADICAVA Business to Shionogi

Ropes & Gray Advised Tanabe Pharma Corporation in the $2.5 Billion Sale of Global Rights to its RADICAVA Business to Shionogi

Ropes & Gray advised Tanabe Pharma Corporation, a Bain Capital portfolio company, in the sale of global rights to RADICAVA, a leading therapy for amyotrophic lateral sclerosis (ALS), to Japanese pharmaceutical company Shionogi. Under the agreement, which was announced on December 22, Shionogi will pay $2.5 billion in upfront consideration to Tanabe Pharma. The transaction is expected to close in the second quarter of 2026, subject to customary regulatory approvals.

The Ropes & Gray team was led by Ray Grant (Partner/ Life Sciences Transaction) and Arthur Mok (Partner/ Life Sciences Transaction), Michael Brueck ( Partner/ Mergers & Acquisitions ), Emily Karlberg (Partner /IP Transaction) and included Tsuyoshi Imai (Partner/ Private Equity) and Ben Morris (Partner/ Private Equity), David Saltzman (Partner/ Tax), Mike McFalls (Partner/ Antitrust) and Ruchit Patel (Partner/ Antitrust), Josh Oyster (Partner/ Life Sciences), Katherine Wang (Partner/ Life Sciences) and Lincoln Tsang (Partner/ Life Sciences), Jamie Darch (Partner/ Health Care) and David Peloquin (Partner/ Health Care), Ellen Sueda (Partner/ Employement, Executive Compensation, Benefit), Geoff Atkins (Partner/ Litigation & Enforcement), Michael Mendel (Tax Counsel), Sean Smith (Counsel/ Employement, Executive Compensation, Benefits) and Elizabeth Whitkin (Counsel/ Health Care).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.